OMER Omeros Corporation

13.31
-1.93  -13%
Previous Close 15.24
Open 13.55
Price To Book -4.74
Market Cap 662,143,458
Shares 49,747,818
Volume 3,100,951
Short Ratio
Av. Daily Volume 421,444
Stock charts supplied by TradingView

NewsSee all news

  1. Omeros Announces Pricing of Upsized Public Offering of Common Stock

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  2. Omeros Announces Proposed Public Offering of Common Stock

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  3. Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab

    – 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA; 68 Percent Primary-Endpoint Complete Response Rate for Those Who

  4. Omeros' New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online

    Omeros Corporation (NASDAQ:OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The

  5. Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston

    -- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- Omeros Corporation (NASDAQ:OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing announced October 28, 2019. To be completed 1H 2020.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Continues to enrol as of August 2019.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 data September 16, 2019 noted treatment was safe and well-tolerated.
OMS527
Nicotine Addiction

Latest News

  1. Omeros Announces Pricing of Upsized Public Offering of Common Stock

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  2. Omeros Announces Proposed Public Offering of Common Stock

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  3. Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab

    – 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA; 68 Percent Primary-Endpoint Complete Response Rate for Those Who

  4. Omeros' New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online

    Omeros Corporation (NASDAQ:OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The

  5. Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston

    -- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- Omeros Corporation (NASDAQ:OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency

  6. Omeros Corporation Reports Third Quarter 2019 Financial Results

    Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for

  7. Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy

    Omeros Corporation (NASDAQ:OMER) today announced an upcoming presentation entitled "Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances

  8. Omeros Scientists Win 2019 Prix Galien Research Award

    --Prestigious Prize Conferred for GPCR Program Discoveries-- Omeros Corporation (NASDAQ:OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A.

  9. Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019

    Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.

  10. Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain

    -- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- Omeros Corporation (NASDAQ:OMER) today announced that results of a prospective, controlled study showing that its FDA-approved

  11. Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA

    – Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020 – Omeros Corporation (NASDAQ:OMER) has submitted the first sections of the rolling submission of its Biologics

  12. Product-Specific J-Code for Omeros' OMIDRIA® is Now in Effect

    Omeros Corporation (NASDAQ:OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros' commercial drug marketed

  13. Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System's Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria

    Omeros Corporation (NASDAQ:OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria

  14. Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction

    -- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- Omeros Corporation (NASDAQ:OMER) today announced positive results from its Phase 1 study with the lead compound in its

  15. FDA Confirms Omeros' Schedule for Rolling Review of the Company's BLA for Narsoplimab in the Treatment of HSCT-TMA

    – Omeros Remains On Track to Initiate the Submission Next Quarter – Omeros Corporation (NASDAQ:OMER) announced that the United States Food and Drug Administration (FDA) agreed with the company's proposed schedule for

  16. Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

    -- The Company's GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- Omeros Corporation (NASDAQ:OMER) today announced a new approach to cancer immunotherapy that targets

  17. Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Omeros Corporation (NASDAQ:OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next